Monitor the SITC 2026 presentations (Nov 6-7) for detailed biomarker data and any updates on the phase 2 trial's durability and systemic immune modulation. The 75% ORR and sustained responses are positive signals, but the company remains pre-revenue and needs additional capital for further development.
Price Chart
How similar events traded
Executive Summary
Evaxion announced new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01 will be presented at the SITC 2026 Annual Meeting. The data show a 75% objective response rate (12/16 patients) in advanced melanoma with sustained clinical and T-cell responses at three-year follow-up. This is a clinical update with no financial results, so no earnings data is reported.
Key Facts
- Phase 2 trial of EVX-01 in advanced melanoma showed 75% ORR (12/16 patients) at two-year follow-up, with 4 complete responses
- 89% of EVX-01 neoantigen targets triggered a tumor-specific immune response
- Clinical and T-cell responses sustained at three-year follow-up
- Data to be presented in oral and poster sessions at SITC 2026 (Nov 4-8, 2026)
- EVX-01 is a personalized peptide-based cancer vaccine designed using Evaxion's AI-Immunology platform
Financial Impact
No financial data in filing; Evaxion is a clinical-stage company with $28M market cap
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Small trial size (16 patients) limits statistical significance
- Need for additional capital to fund ongoing development
- Forward-looking statements subject to clinical trial risks and regulatory uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-007058 |
| Document: f6k_110326.htm | 0001171843-26-007058 |
| Document: 0001171843-26-007058-index-headers.html | 0001171843-26-007058 |
| Document: 0001171843-26-007058-index.html | 0001171843-26-007058 |
| Document: 0001171843-26-007058.txt | 0001171843-26-007058 |
| Earnings Context (Synthetic; results releases only) | 0001171843-26-007058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | 6-K | $3.19 | awaiting T+1 | awaiting T+1 | $3.12 (−2.19%) |
Nov 4, 2026 today | 6-K | $3.19 | awaiting T+1 | awaiting T+1 | $3.12 (−2.19%) |
Nov 3, 2026 1d ago | 6-K | $2.93 | awaiting T+1 | awaiting T+1 | $3.12 (+6.48%) |
Oct 30, 2026 5d ago | 6-K | $2.93 $2.92 | ▼ −0.34% | ▲ +0.14% | $3.12 (+6.48%) |
Oct 30, 2026 5d ago | Press Release | $2.93 $2.92 | ▼ −0.34% | ▲ +0.14% | $3.12 (+6.48%) |
Oct 23, 2026 12d ago | 6-K | $3.76 $3.08 | ▼ −18.09% | ▼ −18.80% | $3.12 (−17.02%) |
Oct 19, 2026 16d ago | 6-K | $3.33 $4.05 | ▲ +21.62% | ▲ +21.29% | $3.12 (−6.31%) |
Oct 2, 2026 4w ago | 6-K | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.12 (−2.50%) |
Oct 2, 2026 4w ago | Press Release | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.12 (−2.50%) |
Sep 14, 2026 7w ago | 6-K | $3.07 $3.04 | ▼ −0.98% | ▼ −0.52% | $3.12 (+1.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers